Charles Russell Speechlys advises Kreos Capital and Silicon Valley Bank on £20 million growth capital investment in Mereo BioPharma
Charles Russell Speechlys have advised Kreos Capital and Silicon Valley Bank on a £20 million growth capital investment in Mereo BioPharma, a UK-based specialty bio-pharmaceutical company listed on the AIM market of the London Stock Exchange.
Mereo BioPharma was established to address the R&D and financial challenges faced by an increasing number of large pharmaceutical and biotech companies, and to optimise drug development and ensure that promising drug candidates fulfil their potential.
Mereo BioPharma announced to the market that it will use the financing to increase its operational and development flexibility.
The Charles Russell Speechlys core team comprised Chris Putt (Partner), Rossana Conti (Senior Associate), Amelly Kok (Associate) and Olivia Mackie (Associate) from our Corporate Team, and Daniel Sullivan (Partner) and Susan Mitchell (Senior Associate) from our Banking Team.”
News & Insights
COVID-19: FCA Measures to aid listed issuers
The FCA issued statement of policy with a temporary relaxation of its rules.
How will COVID-19 affect UK immigration?
Understanding the impact of COVID-19 on the current and future immigration processes.